Denali Therapeutics Inc.

DNLI · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueBalanced
News flowBalanced
MomentumBalanced
SafetyBalanced

Overall confidence 52/100 — a solid read; one perspective is still filling in

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Very high (91/100) · Gap confidence 66/100Documented progress is running well ahead of market attention.

This month at a glance

AIR Score™ change: -2Slipped -2 on softer inputs.

Cycle window9 Sep 2026 → 10 Sep 2026

Momentum-1Weighed on the latest score.

Value-1Weighed on the latest score.

Evidence timeline

[8-K 2.02] Denali Therapeutics Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 6, 2026 · 8-K
[8-K 2.01] Denali Therapeutics Inc. — Completion of Acquisition or Disposition of AssetsSEC · SEC EDGAR
Jul 27, 2026 · 8-K
[8-K 1.01] Denali Therapeutics Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Jun 12, 2026 · 8-K
[8-K 2.02] Denali Therapeutics Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 7, 2026 · 8-K
[8-K 1.02] Denali Therapeutics Inc. — Termination of a Material Definitive AgreementSEC · SEC EDGAR
Apr 3, 2026 · 8-K
[8-K 2.03] Denali Therapeutics Inc. — Creation of a Material Direct Financial ObligationSEC · SEC EDGAR
Mar 27, 2026 · 8-K
[FDA original_approval] Denali Therapeutics Inc. — AVLAYAH (BLA761485/1) — Original NDA/BLA approvalFDA · openFDA drugsfda
Mar 24, 2026 · Original NDA/BLA approval
[8-K 2.02] Denali Therapeutics Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Feb 26, 2026 · 8-K
[8-K 8.01] Denali Therapeutics Inc. — Other EventsSEC · SEC EDGAR
Dec 9, 2025 · 8-K
[8-K 1.01] Denali Therapeutics Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Dec 9, 2025 · 8-K
[8-K 8.01] Denali Therapeutics Inc. — Other EventsSEC · SEC EDGAR
Dec 4, 2025 · 8-K
[8-K 1.01] Denali Therapeutics Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Dec 4, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.